SWK Holdings Corp. has released its results for the first quarter of 2025, showcasing its continued focus on providing custom financing solutions to healthcare companies and royalty owners. As of May 2025, SWK Holdings completed financings with 58 parties, deploying a total of $853 million in capital. The company targets unlevered, mid-teens gross returns on capital, achieving a portfolio effective yield of 14.5% for the first quarter of 2025. Additionally, SWK Holdings reported 44 exits from inception through May 2025, generating a 17.1% internal rate of return $(IRR)$ and a 1.43x multiple on invested capital (MOIC). In terms of shareholder returns, SWK Holdings repurchased 63,000 shares of stock year-to-date as of May 2025, at a total cost of $1.1 million. During 2025, the company monetized its performing royalty book for $51.3 million and subsequently paid a $49.1 million ($4.00 per share) dividend. Looking ahead, the company aims to increase book value per share at a 10% compound annual growth rate $(CAGR)$ and intends to serve as a partner of choice for small and mid-sized life sciences companies and inventors. SWK Holdings also seeks to generate current income to utilize its substantial net operating loss $(NOL.AU)$ asset, which stands at $58.1 million as of December 31, 2024.